anti-alpha 1 Antichymotrypsin / AACT antibody
Contact Us
-
Alternative name
A1 Antichymotrypsin, AACT, ACT, Alpha 1 antichymotrypsin, GIG24, GIG25, Serpin A3, SERPINA3 antibody
-
Catalog
A000318
-
Size100μg
-
Formliquid
-
Purity≥95% as determined by SDS-PAGE
-
StoragePBS with 0.02% sodium azide and 50% glycerol pH 7.3 , -20℃ for 24 months (Avoid repeated freeze / thaw cycles.)
-
ClonalityMonoclonal Antibody
-
Host Mouse
-
Species ReactivityHuman
-
Applications Tested/SuitableELISA,WB,IHC
-
PurificationProtein A+G purification
-
Immunogenserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3
-
IHCImmunohistochemistry of paraffin-embedded human liver using A000318(SERPINA3,AACT antibody) at dilution of 1:50
-
Western Blothuman blood tissue were subjected to SDS PAGE followed by western blot with A000318(SERPINA3,AACT antibody) at dilution of 1:1000
-
Recommended dilutionWB :1:500-1:5000;IHC:1:20-1:200
-
Product Description specificalHuman SerpinA3, also known as Alpha 1-antichymotrypsin (AACT), is a member of the serine protease inhibitor class, and is a plasma alpha globulin glycoprotein which increases in the blood during the inflammatory process. SerpinA3, is also an inhibitor of neutrophil cathepsin G, mast cell chymases and pancreatic chymotrypsin. SerpinA3 is produced primarily in the liver, and is identified as an acute-phase inflammatory protein. SerpinA3 deficiency has been associated with liver disease. SerpinA3 has also been implicated in the pathology of a number of devastating human diseases including chronic obstructive pulmonary disease (COPD), Parkinson’s disease (PD), Alzheimer’s disease (AD), Stroke, Cystic Fibrosis, Cerebral Haemorrhage and Multiple System Atrophy.
-
locationsecreted
-
Uniprot IDP01011
-
Calculated M.W.48kDa,observed 65kDa
-